Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176299 | 0.87 | SMN1; SMN2 (0.54) | NAMPTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL20469627 | 0.80 | MEN1 (0.53) | NAMPTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL13055402 | 0.78 | CYP17A1 (0.59) | NAMPTSMN1; SMN2L3MBTL1CYP17A1PSMB8 | |
| SCHEMBL30531135 | 0.77 | PSMB8 (0.51) | NAMPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL19853212 | 0.77 | NAMPT (0.54) | NAMPTSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL907521 | 0.76 | NAMPT (0.46) | NAMPTSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL29330298 | 0.76 | CYP17A1 (0.49) | NAMPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL28298376 | 0.76 | NAMPT (0.52) | NAMPTSMN1; SMN2L3MBTL1CYP17A1PSMB8 | |
| SCHEMBL907174 | 0.75 | NR1H4 (0.56) | NAMPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL31619134 | 0.75 | MAPT (0.71) | SMN1; SMN2MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | NAMPT 2069/4885SMN1; SMN2 3136/4885MEN1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.